Enveric Biosciences (ENVB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$3.0M

Net income growth (year over year)

−20.19%

Net margin

—

Return on equity

−235.48%

EPS (trailing twelve months)

−$12.18

Book value per share

$2.05

P/E (trailing twelve months)

—

Price to book

0.76

Debt to assets

9.63%

Payout ratio

—

Dividend yield

—

Company profile

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

• How do I buy stock in Enveric Biosciences (ENVB)?

  ENVB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.